Correction: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]
نویسندگان
چکیده
References 1. Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L , Kanis J: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Research 2006, 8:R13. Correction Correction: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] Trevor Powles1, Alexander Paterson2, Eugene McCloskey3, Phil Schein4, Bobbi Scheffler5, Alwynne Tidy6, Sue Ashley6, Ian Smith6, Lars Ottestad7 and John Kanis3
منابع مشابه
Ottestad, J Kanis (2006) Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer
Introduction Experimental and clinical data show that the oral bisphosphonate clodronate (Bonefos®) can inhibit tumorinduced osteoclastic bone resorption. This randomized, doubleblind, placebo-controlled, multicenter trial was designed to determine if the addition of oral clodronate to standard treatment for primary operable breast cancer could reduce the subsequent occurrence of bone metastase...
متن کاملOral bisphosphonates as adjuvant therapy for operable breast cancer.
Bone is the most common site of metastatic spread from primary operable breast cancer, causing pain, fractures, and hypercalcemia. This spread depends on the release of osteolytic substances by the cancer cells, which activate osteoclasts to cause bone resorption. The osteoclasts also release growth factors that can act back on the cancer cells to activate growth. This vicious circle thereby fa...
متن کاملAdjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up.
BACKGROUND Adding oral clodronate to postoperative adjuvant breast cancer therapy significantly improves disease-free survival (DFS) and overall survival (OS). Long-term follow-up data from the prospective, randomized, controlled study are reported. PATIENTS AND METHODS Patients with primary breast cancer received clodronate 1600 mg/day for 2 years or no treatment along with standard adjuvant...
متن کاملA systematic review of the role of bisphosphonates in metastatic disease.
OBJECTIVES To identify evidence for the role of bisphosphonates in malignancy for the treatment of hypercalcaemia, prevention of skeletal morbidity and use in the adjuvant setting. To perform an economic review of current literature and model the cost effectiveness of bisphosphonates in the treatment of hypercalcaemia and prevention of skeletal morbidity. DATA SOURCES Electronic databases (19...
متن کاملBisphosphonates and breast cancer incidence and recurrence.
Bisphosphonates are commonly used in patients with breast cancer to reduce skeletal-related events in metastatic disease and to mitigate bone loss associated with adjuvant therapy. Preclinical studies have shown that bisphosphonates may directly inhibit breast cancer cell proliferation and metastasis. Clinical trials evaluating the oral bisphosphonate clodronate as a component of adjuvant thera...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Breast Cancer Research
دوره 8 شماره
صفحات -
تاریخ انتشار 2006